

SPONSOR

# ASGCT Insights



ASGCT Insights is a series of five scientific symposia presented virtually in the month of October. This virtual event will explore novel topics not typically discussed at the Annual Meeting.

- \$50 for ASGCT Members, \$100 for non-members per session
- Relevant, timely topics in the gene and cell field
- Targeted to researchers, clinicians, industry professionals, regulatory agencies, and patient advocates

FOUR WAYS TO SUPPORT

## Sponsorship Opportunities

1

### \$5,000 Gold Sponsor

Benefits include:

- Logo on the Insight Series event webpage
- Logo on opening slides of series
- Two complimentary registrations

2

### \$2,500 Silver Sponsor

Benefits include:

- Logo scaled to 75% on the Insight Series event webpage
- Logo scaled to 75% on opening slides of series
- One complimentary registration

3

### \$1,000 Bronze Sponsor

Benefits include:

- Logo scaled to 50% on the Insight Series event webpage
- Logo scaled to 50% on opening slides of series

4

### \$3,000 Pre-Recorded Video

General information:

- One 15-minute pre-recorded video embedded onto the online event page
- Limited to one video per topic
- Silver sponsor benefits

# Winter 2023 Insight Series

## UPCOMING TOPICS

### October 16

Best of ASGCT Annual Meetings: Recent Top Abstracts Revisited

- This event will revisit the top abstracts from the past Annual Meetings with presentations that cover post Annual Meeting research and findings. Presentations will cover a variety of topics including hematopoietic reconstitution, regulatory T-cells in type I diabetes, and prime editing in Sickle Cell.

### October 17

Risk Assessment of Lentiviral and AAV Gene Therapy Vectors

- A key factor to successful gene therapy is efforts to monitor the fate of gene-corrected cells. Lentivirus and AAV vectors can efficiently introduce new genetic material into human cells however it also risks genotoxicity and malignant transformation. This panel of experts will discuss state-of-the-art technologies and assays for integration site profiling, clonality and oncogenesis.

### October 18

Risk Assessment of Gene Editing Technologies and Outcomes

- Emerging technologies seek to avoid risks associated with genomic cleavage/repair through single base editing. Discussions will focus on state-of-the-art technologies and assays for integration site profiling, clonality and oncogenesis. Also to be discussed is the translational and regulatory utility of these data for supporting ongoing and future human gene therapy studies.

### October 19

Treating Genetic Diseases Prior to Birth, From Stems Cells to Gene Delivery

- In utero stem cell transplantation (IUTx) and in utero gene therapy (IUGT) offer the opportunity of treating, and ideally curing, a wide range of genetic disorders. Despite recent progress, there is an urgent need to explore novel cell and gene therapy tools for prenatal application and to explore the ethical considerations surrounding this topic.

### October 20

Friend or Foe? Interplay Between Innate Immune Responses and Non-viral Gene Delivery

- This Insights program will illustrate recent advances in our understanding of how pathogen recognition and consequent innate immune signaling may impact non-viral delivery of nucleic acids for better or for worse.

[Learn more about each session here.](#)

[Watch past sessions here.](#)